

February 6, 2020

Octapharma's Panzyga® (Intravenous Immunoglobulin, IVIG): An established IVIG available through Canadian Blood Services (CBS)

Dear Health Care Professional,

We are pleased to announce the continued availability of Panzyga® (IVIG, Octapharma) for your patients through the CBS order form. Panzyga® is a sterile liquid preparation of highly purified immunoglobulin G (IgG) for intravenous administration. It is approved in Canada for the treatment of patients with primary immune deficiency (PID) and secondary immune deficiency (SID), immune thrombocytopenic purpura (ITP), and moderate to severe Guillain-Barré Syndrome (GBS). The safety and efficacy of Panzyga® has been established through well controlled clinical studies. Since its introduction, more than 3 million grams of Panzyga® have been infused in Canadian patients.

Indication ¹	Recommended Dose ¹
Treatment of PID and SID	200 to 800 mg/kg every 3 – 4 weeks
Treatment of ITP	2 g/kg, in two doses of 1 g/kg (10 mL/kg) given on 2 consecutive days
Treatment of moderate to severe GBS	2 g/kg (20 mL/kg) given in divided doses over 2-5 consecutive days

Panzyga® is prepared from large pools of US or Canadian human plasma. Pathogen inactivation/removal is ensured by solvent/detergent (S/D) method and nanofiltration (20 nm), supplemented by ion-exchange chromatography¹. It is a 100 mg/mL solution for intravenous infusion, available in 3 convenient vial sizes: 5g, 20g, and 30g. It can be stored at +2 °C to +8 °C for 36 months from the date of manufacture. Within this shelf-life the product may be stored up to 12 months at ≤ 25°C¹.

Important Safety Information: As with all immunoglobulins Panzyga® is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of a human immunoglobulin preparation. Panzyga® is contraindicated in individuals with selective IgA deficiency with known anti-IgA antibodies. For complete prescribing information, refer to the Panzyga® Product Monograph [here](#). For additional medical information contact medinfo.canada@octapharma.com or call 1-888-438-0488.

Sincerely,

Sri Adapa
General Manager

Ref: Panzyga® Canadian Product Monograph, August 22, 2019

Octapharma Canada Inc.
308-214 King Street West
Toronto, ON M5H 3S6

Phone: +1 (416) 531-5533
Email: info@octapharma.ca